Carcinoma
|
0.370 |
Biomarker
|
group |
BEFREE |
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
|
27581603 |
2016 |
Carcinoma
|
0.370 |
AlteredExpression
|
group |
BEFREE |
Only in LC-positive carcinomas did epithelial cells close to lymphoid aggregates display small amounts of GM-CSF and TNF alpha mRNA expression.
|
7635448 |
1995 |
Carcinoma
|
0.370 |
Therapeutic
|
group |
CTD_human |
Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A.
|
11605069 |
2001 |
Carcinoma
|
0.370 |
Biomarker
|
group |
BEFREE |
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
|
15613691 |
2005 |
Carcinoma
|
0.370 |
AlteredExpression
|
group |
BEFREE |
Our data show that the LNCaP cells express functional GM-CSF receptors and that prostatic carcinomas have prominent GM-CSF receptor expression.
|
9446667 |
1998 |
Carcinoma
|
0.370 |
Biomarker
|
group |
BEFREE |
Magmas, a conserved mammalian protein essential for eukaryotic development, is overexpressed in prostate carcinomas and cells exposed to granulocyte-macrophage colony-stimulating factor (GM-CSF).
|
20053669 |
2010 |
Carcinoma
|
0.370 |
Biomarker
|
group |
BEFREE |
(c) Some, but not all, lung carcinomas produced this cytokine, and a close correlation was found between the production of GM-CSF and the number of CD1a+ LC infiltrating these tumors.
|
7679411 |
1993 |
Carcinoma
|
0.370 |
Biomarker
|
group |
BEFREE |
Recent research found abnormal expression of the c-fms oncogene, which encodes the macrophage colony-stimulating factor receptor (CSF-1R), in several human carcinomas including hepatocellular carcinoma (HCC).
|
14969845 |
2004 |
Liver neoplasms
|
0.360 |
Therapeutic
|
group |
CTD_human |
Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors.
|
17326190 |
2007 |
Liver neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
The results showed that combined gene transfer of p21WAF-1 and GM-CSF could inhibit the growth of pre-established tumor more effectively and prolong the survival time of hepatoma-bearing mice more significantly than the transfer of a single gene.
|
11916239 |
2002 |
Liver neoplasms
|
0.360 |
GeneticVariation
|
group |
BEFREE |
To test whether antitumor activity could be increased by combining the above two mechanisms, this study examined the therapeutic effect of combination gene therapy using a murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) gene and a human endostatin (hED) gene on a rat orthotopic liver tumor model.
|
12731087 |
2003 |
Liver neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Therefore, these results suggest that combining expression of GM-CSF and B70 may enhance NK-mediated cytotoxicity, and then induce the antitumor immunity in hepatoma transplanted into nude mice.
|
11295284 |
2001 |
Liver neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
The distant bystander effect was associated with a strong induction of GMCSF and IL-12 expression in the untreated TK-negative liver tumors.
|
11880183 |
2002 |
Liver neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors.
|
17326190 |
2007 |
Liver neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
The results demonstrated that combined administration of p21(WAF-1) and GM-CSF could remarkably inhibit the growth of subcutaneously transplanted hepatoma Hepa cells, and significantly increase the survival rate of tumor-bearing mice.
|
12833133 |
2003 |
Mammary Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
First, immunotherapy with an allogeneic, HER2-positive, GM-CSF-secreting breast tumor vaccine alone or with CY and DOX is safe and induces HER2-specific immunity in patients with metastatic breast cancer.
|
19805669 |
2009 |
Mammary Neoplasms
|
0.350 |
Therapeutic
|
group |
CTD_human |
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
|
11325840 |
2001 |
Mammary Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Thus, we explored the potential immune-modulating effects of sorafenib in a murine HER-2-(neu) overexpressing breast tumor model alone and in combination with a HER-2 targeted granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting vaccine (3T3neuGM).
|
28282575 |
2017 |
Mammary Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
We have previously reported that, in a phase I pilot study (ClinicalTrials.gov NCT00095862), a subject with stage IV breast cancer experienced substantial regression of breast, lung, and brain lesions following inoculation with clinical formulations of SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line.
|
29867922 |
2018 |
Mammary Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
|
20127358 |
2010 |
Mammary Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
|
12748184 |
2003 |
Sarcoma
|
0.330 |
Biomarker
|
group |
BEFREE |
The efficacy of Ad5/3-D24-GMCSF was evaluated on a panel of soft-tissue sarcoma (STS) cell lines and in two animal models.
|
24374597 |
2014 |
Sarcoma
|
0.330 |
Therapeutic
|
group |
CTD_human |
The effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in two experimental tumor models, 3MC-induced MHC class I+ sarcoma Mc12 and HPV16 E6/E7 oncogene-induced MHC class I- carcinoma MK16, transplanted in syngeneic mice.
|
11605069 |
2001 |
Sarcoma
|
0.330 |
Biomarker
|
group |
BEFREE |
The v-fms oncogene of the McDonough strain of feline sarcoma virus (SM-FeSV) encodes a plasma-membrane-associated tyrosine kinase (gp140v-fms) which is closely related, both structurally and functionally, to the c-fms-specified receptor for the macrophage colony stimulating factor (CSF-1).
|
2171188 |
1990 |
Sarcoma
|
0.330 |
GeneticVariation
|
group |
BEFREE |
As described in this protocol, fresh human sarcoma and melanoma specimens can be transfected with the GM-CSF DNA-coated gold particles with subsequent production of biologically active GM-CSF protein.
|
9143914 |
1997 |